Alamar Biosciences Targets $9 Billion Diagnostics Market as Instrument Pull-Through Signals Early Commercial Traction
Morgan Stanley 24th Annual Global Healthcare Conference, September 15, 2026
Alamar Biosciences used its appearance at Morgan Stanley's Global Healthcare Conference to lay out a more granular picture of how its precision proteomics platform is scaling, with CEO Yuling Luo and CFO Justin McAnear providing investors fresh detail on unit economics, competitive moat, and the path toward FDA clearance for its diagnostics ambitions. The company, still early in its commercial life, is positioning NULISA as the only platform combining ultra-high sensitivity, specificity, multiplex capability, broad dynamic range, and full automation in a single system, a claim management argues creates durable differentiation against both mass spec and single-plex immunoassay incumbents.
Pull-Through Economics Reveal Significant Headroom
The most concrete new data point for investors centered on consumables pull-through, the key razor-and-blade metric for the business. McAnear disclosed that instrument pull-through is currently running north of $400,000 annually, a figure the company has set as its 2026 target, but he also quantified the theoretical ceiling for the first time: over $6 million per instrument if run at full capacity. The math is straightforward. A single plate holds 86 samples and costs $9,000 to $10,000; running two plates weekly would already double current pull-through to roughly $800,000, while loading the instrument to run three plates in sequence four to five days a week gets to the multimillion-dollar ceiling. That gap between current utilization and theoretical capacity is a central part of the bull case, though McAnear was careful to flag that the metric will fluctuate quarter to quarter, particularly as new instrument placements grow and seasonality weighs on year-end results, which is why the company has chosen to report it annually rather than quarterly.
Consumables revenue nearly tripled year-over-year in the second quarter, a growth rate that outpaces instrument placement growth and suggests existing customers are ramping usage meaningfully. Biopharma customers behave differently than academic core labs in this regard: pharma is more willing to buy a second, third, or even sixth instrument quickly because turnaround time matters more than capital efficiency, while academic core labs tend to maximize utilization on a single instrument before adding capacity. That bifurcation matters for modeling forward pull-through, since a pharma-heavy mix could show lower per-instrument consumables revenue even as aggregate demand signals strengthen.
Gross Margin Cadence and Mix Shift
McAnear confirmed the company crossed 60% gross margin for the first time in the second quarter, calling it a milestone, but guided investors to think about near-term margins in the mid-to-high 50s given quarter-to-quarter mix volatility. The mechanics are simple: consumables carry meaningfully higher margins than instruments, with services falling in between, so as the installed base grows and consumable revenue becomes a larger share of the mix, blended margins should trend higher. McAnear also pointed to a separate lever, economies of scale within consumables manufacturing as batch sizes increase, plus a stated "path to improving the instrument gross margins as well," suggesting margin expansion is not solely a function of mix shift but also of manufacturing efficiency gains still ahead.
Commercial Momentum and Sales Force Productivity
The company reiterated its goal of 100 instrument placements in 2026, with McAnear noting that most placements to date have gone to new customers, though a "meaningful amount" reflects existing customers buying additional units. Notably, he flagged growing traction among contract research organizations this year, framing CRO instrument purchases as a leading indicator of anticipated downstream biopharma demand. On sales productivity, the company ended last year at roughly $3 million of revenue per commissioned sales rep, a figure McAnear said is now "a decent amount above" that level. Management was explicit that it will prioritize continued investment in headcount over maximizing per-rep efficiency, a signal that near-term operating expense growth should track revenue ambitions rather than cost discipline.
Diagnostics Pathway and FDA Timeline
On the regulatory front, Alamar reaffirmed its plan to submit its ARGO HT/DX platform for FDA clearance by the end of 2027, combining the diagnostic instrument with an assay the company has not yet disclosed publicly. Luo confirmed the company has already completed a pre-submission meeting with the FDA, giving management visibility into the agency's expectations for analytical and clinical validation work still ahead, which will require full cGMP manufacturing, analytical performance validation, and clinical validation. Luo argued that clearance would have a self-reinforcing effect on the research business as well, telling investors that FDA authorization would spur diagnostic labs and IVD companies to partner on differentiated multiplex tests, while pharma customers who prioritize data quality and regulatory rigor would likely expand platform usage from discovery into clinical trials and companion diagnostics. This is a claim worth scrutinizing rather than accepting at face value, since it assumes clearance timing holds and that partner economics materialize as described.
Technology Moat and Competitive Positioning
Luo was direct about what he views as the company's defensibility: a chemistry approach that suppresses background noise to achieve what he described as a roughly 10,000-fold improvement in signal-to-noise ratio, protected by both issued patents and trade secrets accumulated over six years of pre-launch development. He drew a direct parallel to his prior company's RNAscope technology, noting that "20 years later, the patent has expired, but still nobody is able to replicate what we did," a comment investors should treat as a data point on the durability of trade-secret protection but not a guarantee that Alamar's moat will prove equally durable in a more competitive proteomics landscape than RNA in situ hybridization faced.
Custom Assay Optionality
One underappreciated element of the model is the Technology Access Program, which functions both as a new-customer acquisition funnel and a custom assay development engine for biopharma partners. Luo highlighted IL-31, an atopic dermatitis drug target that is difficult to measure due to low abundance, as an example where Alamar developed a proprietary assay that multiple pharma and biotech companies have since requested, giving management confidence there is a broader commercial market to convert into a standard offering. Critically, Alamar retains commercialization rights to target-based assays developed through this program, creating a call option on future high-margin consumables revenue beyond the current Neuro 220 and Immune 340 panel franchises.
Market Sizing and Total Addressable Opportunity
Management reiterated its long-standing $50 billion total addressable market framing but added new segmentation detail. The advanced proteomics research market is roughly $3.7 billion today, expected to grow to approximately $11 billion, while the clinical diagnostics opportunity enabled by advanced proteomics is currently only about $400 million but is projected to reach $9 billion by 2035, driven primarily by Alzheimer's disease applications. Investors should note this diagnostics figure remains a forecast dependent on regulatory clearance and adoption curves that have not yet been proven at scale, making the 2027 FDA submission timeline a critical catalyst to track.